13F reference period
Q2 2026
Security Snapshot
Q32 Bio Inc. - Common Stock, $0.00001 par value (QTTB) Institutional Ownership
CUSIP: 746964105
13F Institutional Holders and Ownership History from Q1 2024 to Q3 2026
Institutions Reporting
70
Shares (Excl. Options)
22,179,033
Price
$12.74
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.00001 par value
- Symbol
- QTTB on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 22,179,033
- Total 13F value
- $282,559,680
- Portfolio coverage rank
- 0%
- Share change
- +12,748,684
- Value change
- +$166,954,159
- Number of holders
- 70
- Shares outstanding
- 29,747,729
- SEC-reported price per share
- $8.28
- Insider filing price
- $8.28
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- QTTB - Q32 Bio Inc. - Common Stock, $0.00001 par value is tracked under CUSIP 746964105.
- 70 institutions reported positions in Q2 2026.
- 11 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 53 to 70 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $60,617,009 to $282,559,680.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 70 institutions filings for Q2 2026.
Security key
746964105
13F reference period
Q2 2026
13F holders
70
13D/G owners
11
CIK / CUSIP context first
Open Q2 2026 holders
QTTB full holder history
Q32 Bio Inc. SEC filings
Q32 Bio Inc. company facts
Q32 Bio Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 746964105:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
11
Security
QTTB
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 14% | -21% | $49,329,445 | 4,127,987 | 0% | ORBIMED ADVISORS LLC | 16 Jul 2026 | |
| Boxer Capital Management, LLC | 13% | $37,886,199 | 3,149,310 | Boxer Capital Management, LLC | 30 Jun 2026 | |||
| BIOTECHNOLOGY VALUE FUND L P | 10% | $13,021,382 | 2,367,524 | BVF PARTNERS L P/IL | 28 May 2026 | |||
| RA CAPITAL MANAGEMENT, L.P. | 9.8% | $12,828,514 | 2,332,457 | RA Capital Management, L.P. | 28 May 2026 | |||
| Frazier Life Sciences Public Fund, L.P. | 5.9% | $19,481,788 | 1,755,116 | Frazier Life Sciences Public Fund, L.P. | 02 Oct 2026 | |||
| Point72 Asset Management, L.P. | 5% | -12% | $25,087,206 | +$4,588,747 | 1,173,396 | +22% | Point72 Asset Management, L.P. | 30 Jun 2026 |
| Opaleye Management Inc. | 5.5% | -34% | $19,904,780 | -$6,953,375 | 931,000 | -26% | Opaleye Management Inc. | 30 Jun 2026 |
| Atlas Venture Fund X, L.P. | 3.6% | $4,753,436 | 864,261 | Atlas Venture Fund X, L.P. | 26 May 2026 | |||
| Carlyle Group Inc. | 4.1% | $8,321,572 | 691,735 | The Carlyle Group Inc. | 30 Jun 2026 | |||
| PFIZER INC | 2.3% | $994,442 | 277,777 | Pfizer Inc. (IRS Identification No.: 13-5315170) | 31 Dec 2024 | |||
| BRISTOL MYERS SQUIBB CO | 1.6% | $312,381 | 200,244 | BRISTOL MYERS SQUIBB CO | 31 Dec 2024 |
As of 30 Jun 2026, 70 institutional investors reported holding 22,179,033 shares of Q32 Bio Inc. - Common Stock, $0.00001 par value (QTTB). This represents 75% of the company’s total 29,747,729 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
73%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 14% | 4,127,987 | +83% | 1% | $52,590,554 |
| Boxer Capital Management, LLC | 11% | 3,149,310 | 3% | $40,122,209 | |
| Atlas Venture Life Science Advisors, LLC | 9.1% | 2,717,106 | +30% | 3.9% | $34,615,930 |
| BVF INC/IL | 7.9% | 2,350,000 | 0.77% | $29,939,000 | |
| RA CAPITAL MANAGEMENT, L.P. | 7.8% | 2,332,457 | 0.26% | $29,715,502 | |
| Point72 Asset Management, L.P. | 3.9% | 1,173,396 | 0.02% | $14,949,065 | |
| Opaleye Management Inc. | 3.1% | 931,000 | -26% | 1.1% | $11,860,940 |
| Logos Global Management LP | 2.7% | 800,000 | 0.44% | $10,192,000 | |
| SummitTX Capital, L.P. | 2.5% | 733,774 | 0.25% | $9,348,281 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 1.7% | 518,803 | +69% | 0% | $6,609,550 |
| Ikarian Capital, LLC | 1.4% | 430,000 | 0.9% | $5,478,200 | |
| Woodline Partners LP | 0.96% | 286,212 | 0.01% | $3,646,341 | |
| AMERICAN CENTURY COMPANIES INC | 0.92% | 272,752 | +1353% | 0% | $3,474,860 |
| Sanofi | 0.82% | 244,083 | 0% | 0.58% | $3,109,617 |
| ACADIAN ASSET MANAGEMENT LLC | 0.73% | 218,234 | +26% | 0% | $2,779,000 |
| ACORN CAPITAL ADVISORS, LLC | 0.73% | 216,171 | -31% | 0.75% | $2,754,019 |
| RENAISSANCE TECHNOLOGIES LLC | 0.6% | 179,600 | -13% | 0% | $2,288,104 |
| JANE STREET GROUP, LLC | 0.55% | 162,747 | +148% | 0% | $2,073,396 |
| MONIMUS CAPITAL MANAGEMENT, LP | 0.44% | 132,036 | -1.7% | 0.43% | $1,682,139 |
| BOOTHBAY FUND MANAGEMENT, LLC | 0.44% | 130,427 | 0.03% | $1,661,640 | |
| GEODE CAPITAL MANAGEMENT, LLC | 0.41% | 122,690 | +3.8% | 0% | $1,563,506 |
| CITADEL ADVISORS LLC | 0.41% | 120,663 | +679% | 0% | $1,537,247 |
| BlackRock, Inc. | 0.4% | 118,507 | +38% | 0% | $1,509,780 |
| MARSHALL WACE, LLP | 0.23% | 67,045 | +28% | 0% | $854,153 |
| VANGUARD FIDUCIARY TRUST CO | 0.22% | 66,217 | +32% | 0% | $843,605 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
11
Headline period
Q2 2026
Rows shown
1-11 of 11
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 362 | $2,995 | +$819 | $8.27 | 3 |
| 2026 Q2 | 22,179,033 | $282,559,680 | +$166,954,159 | $12.74 | 70 |
| 2026 Q1 | 9,428,888 | $60,617,009 | +$9,025,150 | $6.42 | 53 |
| 2025 Q4 | 8,043,846 | $26,659,216 | -$1,063,038 | $3.32 | 51 |
| 2025 Q3 | 8,428,600 | $16,632,224 | -$986,951 | $1.98 | 52 |
| 2025 Q2 | 8,978,370 | $13,355,302 | -$657,201 | $1.49 | 59 |
| 2025 Q1 | 9,406,123 | $15,511,257 | -$5,227,234 | $1.65 | 71 |
| 2024 Q4 | 10,994,953 | $37,808,803 | -$51,251,129 | $3.44 | 88 |
| 2024 Q3 | 9,108,413 | $405,845,227 | +$55,628,540 | $44.62 | 71 |
| 2024 Q2 | 8,065,328 | $144,178,979 | +$11,388,677 | $17.95 | 54 |
| 2024 Q1 | 7,430,290 | $125,894,701 | +$125,894,701 | $17.04 | 38 |